Mitchel S. Berger, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Mitchel S. Berger, MD

Chair, Department of Neurological Surgery, and Director, Brain Tumor Research Center, UCSF
Berthold and Belle N. Guggenhime Professorship, UCSF

bergerm@neurosurg.ucsf.edu

Phone: (415) 353-3933 (academic); (415) 353-7500 (clinic)
Box 0112, UCSF
San Francisco, CA 94143-0112

UCSF Profiles | Physician Referral Directory

Cancer Center Membership

Program Member » Neurologic Oncology

Research Summary

Dr. Berger's main clinical interests are the treatment of brain tumors in adults and children and of epilepsy related to brain tumors. He has extensive expertise in intraoperative mapping of the brain to identify the sites of motor, sensory, and language function and thereby avoid their involvement or injury during surgery.

Dr. Berger is Director of the Neuro-Oncology Surgery Program. His current research interests involve identifying molecular markers in gliomas as correlates of tumor progression and prognosis. He also works in conjunction with Dr. Krys Bankiewicz to test small molecule inhibitors in brain tumors using convection enhanced delivery. Other collaborations include functional mapping localization of language pathways in the brain in conjunction with Dr. Robert Knight and the Cognitive Neuroscience Graduate Program at UC Berkeley. Dr. Berger is currently the Principal Investigator of UCSF's SPORE Brain Tumor Program. He is also the Principal Investigator of a Pediatric Brain Tumor Foundation Institute award to study the origins and treatment of pediatric brain tumors.

Education

Harvard University, Cambridge, MA, A.B., 1975, Social Psychology
University of Miami, Miami, FL, M.D., 1979, Medicine
University of California, San Francisco, CA (UCSF), Dept. of Neurological Surgery, Brain Tumor Research Center (BTRC) Research Fellow 1983 - 1984 Neurosurgery
UCSF, BTRC, Neuro-Oncology Service, Clinical Fellow, 7/85 - 12/85, Neurosurgery
Hospital for Sick Children, Toronto, Ontario, Canada, Pediatric Neurosurgery Fellow, 1/86 - 6/86, Neurosurgery


Professional Experience

  • 1980 - 1982
    Residency, Dept. of Neurological Surgery, University of California, San Francisco, CA (UCSF)
  • 1986 - 1992
    Asst. Professor, Dept. of Neurological Surgery, University of Washington, Seattle, WA
  • 1990 - 1992
    Assoc. Professor, Dept. of Neurological Surgery, University of Washington, Seattle, WA
  • 1995 - 1992
    American Cancer Society Prof. of Clinical Oncology, University of Washington, Seattle, WA
  • 1996 - 1992
    Professor, Dept. of Neurological Surgery, University of Washington, Seattle, WA
  • 1997 - present
    Professor and Chair, Dept. of Neurological Surgery, UCSF, San Francisco, CA
  • 1997 - present
    Director, Brain Tumor Research Center, Dept. of Neurological Surgery, UCSF

Honors & Awards

  • 1997-Present
    Joint Section on Tumors Advisory Council, American Association of Neurological Surgeons and Congress of Neurological Surgeons
  • 1997-1999
    Vice-President, Congress of Neurological Surgeons; President, Society for Neuro-Oncology
  • 2002-Present
    America’s Top Doctors, peer-nominated referral index from Castle Connolly
  • 2006
    Tumor Section, 2006 Ronald L. Bittner Lecturer; 2006 Farber Award Winner
  • 2007–Present
    Board of Directors of the American Association of Neurological Surgeons
  • 2007–Present
    Member of the American Board of Neurological Surgeons
  • 2010
    Vice-President, American Association of Neurological Surgeons
  • 2011
    President Elect, American Association of Neurological Surgeons
  • 2012
    President, American Association of Neurological Surgeons

Selected Publications

  1. Hu B, Wang Q, Wang YA, Hua S, Sauvé CG, Ong D, Lan ZD, Chang Q, Ho YW, Monasterio MM, Lu X, Zhong Y, Zhang J, Deng P, Tan Z, Wang G, Liao WT, Corley LJ, Yan H, Zhang J, You Y, Liu N, Cai L, Finocchiaro G, Phillips JJ, Berger MS, Spring DJ, Hu J, Sulman EP, Fuller GN, Chin L, Verhaak RG, DePinho RA. Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth. Cell. 2016 Nov 17; 167(5):1281-1295.e18.
    View on PubMed
  2. Winkler EA, Birk H, Safaee M, Yue JK, Burke JF, Viner JA, Pekmezci M, Perry A, Aghi MK, Berger MS, McDermott MW. Surgical resection of fourth ventricular ependymomas: case series and technical nuances. J Neurooncol. 2016 Nov; 130(2):341-349.
    View on PubMed
  3. Grossauer S, Koeck K, Murphy NE, Meyers ID, Daynac M, Truffaux N, Truong AY, Nicolaides TP, McMahon M, Berger MS, Phillips JJ, James CD, Petritsch CK. Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model. Oncotarget. 2016 Oct 3.
    View on PubMed
  4. Han SJ, Reis G, Kohanbash G, Shrivastav S, Magill ST, Molinaro AM, McDermott MW, Theodosopoulos PV, Aghi MK, Berger MS, Butowski NA, Barani I, Phillips JJ, Perry A, Okada H. Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. J Neurooncol. 2016 Dec; 130(3):543-552.
    View on PubMed
  5. Griswold D, Benet A, Berger MS, Lawton MT. Meeting the Unmet Need: Training General Surgeons to Perform Life-Saving Neurosurgical Procedures in Low-Resource Settings. World Neurosurg. 2016 Sep; 93:474.
    View on PubMed
  6. Han SJ, Chang SM, Berger MS. Laser Ablation vs Open Resection for Deep-Seated Tumors: The Case for Open Resection. Neurosurgery. 2016 Aug; 63 Suppl 1:10-4.
    View on PubMed
  7. Barajas RF, Butowski NA, Phillips JJ, Aghi MK, Berger MS, Chang SM, Cha S. The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma. Acad Radiol. 2016 Sep; 23(9):1073-82.
    View on PubMed
  8. Imber BS, Kanungo I, Braunstein S, Barani IJ, Fogh SE, Nakamura JL, Berger MS, Chang EF, Molinaro AM, Cabrera JR, McDermott MW, Sneed PK, Aghi MK. Indications and Efficacy of Gamma Knife Stereotactic Radiosurgery for Recurrent Glioblastoma: 2 Decades of Institutional Experience. Neurosurgery. 2016 Jul 13.
    View on PubMed
  9. Rhodes CT, Sandstrom RS, Huang SA, Wang Y, Schotta G, Berger MS, Lin CA. Cross-species Analyses Unravel the Complexity of H3K27me3 and H4K20me3 in the Context of Neural Stem Progenitor Cells. Neuroepigenetics. 2016 Jun; 6:10-25.
    View on PubMed
  10. Winkler EA, Yue JK, Burke JF, Chan AK, Dhall SS, Berger MS, Manley GT, Tarapore PE. Adult sports-related traumatic brain injury in United States trauma centers. Neurosurg Focus. 2016 Apr; 40(4):E4.
    View on PubMed
  11. Yue JK, Winkler EA, Burke JF, Chan AK, Dhall SS, Berger MS, Manley GT, Tarapore PE. Pediatric sports-related traumatic brain injury in United States trauma centers. Neurosurg Focus. 2016 Apr; 40(4):E3.
    View on PubMed
  12. Ban VS, Bailes JE, Berger MS, Vaccaro AR, Hunt Batjer H. Introduction: Sports injuries: diagnosis and management strategies. Neurosurg Focus. 2016 Apr; 40(4):E2.
    View on PubMed
  13. Jalbert LE, Neill E, Phillips JJ, Lupo JM, Olson MP, Molinaro AM, Berger MS, Chang SM, Nelson SJ. Magnetic resonance analysis of malignant transformation in recurrent glioma. Neuro Oncol. 2016 Aug; 18(8):1169-79.
    View on PubMed
  14. Drilon A, Li G, Dogan S, Gounder M, Shen R, Arcila M, Wang L, Hyman DM, Hechtman J, Wei G, Cam NR, Christiansen J, Luo D, Maneval EC, Bauer T, Patel M, Liu SV, Ou SH, Farago A, Shaw A, Shoemaker RF, Lim J, Hornby Z, Multani P, Ladanyi M, Berger M, Katabi N, Ghossein R, Ho AL. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann Oncol. 2016 May; 27(5):920-6.
    View on PubMed
  15. Dasgupta T, Olow AK, Yang X, Hashizume R, Nicolaides TP, Tom M, Aoki Y, Berger MS, Weiss WA, Stalpers LJ, Prados M, James CD, Mueller S, Haas-Kogan DA. Erratum to: Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. J Neurooncol. 2016 Feb; 126(3):395.
    View on PubMed
  16. Berger MS, Weller M. Preface. Handb Clin Neurol. 2016; 134:ix.
    View on PubMed
  17. Berger MS, Hervey-Jumper S, Wick W. Astrocytic gliomas WHO grades II and III. Handb Clin Neurol. 2016; 134:345-60.
    View on PubMed
  18. Imber BS, Braunstein SE, Wu FY, Nabavizadeh N, Boehling N, Weinberg VK, Tihan T, Barnes M, Mueller S, Butowski NA, Clarke JL, Chang SM, McDermott MM, Prados MD, Berger MS, Haas-Kogan DA. Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience. J Neurooncol. 2016 Jan; 126(1):193-200.
    View on PubMed
  19. Walsh KM, Codd V, Rice T, Nelson CP, Smirnov IV, McCoy LS, Hansen HM, Elhauge E, Ojha J, Francis SS, Madsen NR, Bracci PM, Pico AR, Molinaro AM, Tihan T, Berger MS, Chang SM, Prados MD, Jenkins RB, Wiemels JL. Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk. Oncotarget. 2015 Dec 15; 6(40):42468-77.
    View on PubMed
  20. Tarapore PE, Picht T, Bulubas L, Shin Y, Kulchytska N, Meyer B, Berger MS, Nagarajan SS, Krieg SM. Safety and tolerability of navigated TMS for preoperative mapping in neurosurgical patients. Clin Neurophysiol. 2016 Mar; 127(3):1895-900.
    View on PubMed

Go to UCSF Profiles, powered by CTSI